The Immuno-Oncology Transformation: Implications for Managed Care
Jointly provided by
Impact Education, LLC    
This activity is supported by independent educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

You Are Invited to a LIVE CME/CPE/CNE Webcast Series:
The Immuno-Oncology Transformation: Implications for Managed Care
Live Webcast

Live Webcast Dates

Thursday April 18, 2019 12:30 PM - 2:00 PM ET
Wednesday May 22, 2019 12:30 PM - 2:00 PM ET

Click here to download the slides from this webcast.

Coming Soon: On-demand CE Archive of this Live Webcast

  • Key outcomes measures in immuno-oncology
  • MOAs of novel immuno-oncology agents
  • Payer cost-sharing and benefit design approaches to innovative immuno-oncology agents
  • Initiatives for the funding and management of PD-1/PD-L1 inhibitors and CAR-T therapies
Jeffrey Dunn, PharmD, MBA
Vice President, Clinical Strategy and Programs and Industry Relations
Magellan Rx Management
John Fox, MD, MHA
Vice President, Associate Chief Medical Officer
Medical Affairs
Priority Health
Joan H. Schiller, MD
University of Virginia

  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, registered nurses, quality directors, care managers, and other managed care and payer organization professionals

The recent emergence of immuno-oncology agents has demonstrated promise for further revolutionizing cancer care. True to their name, these drugs extend the concept of targeted cancer therapies by leveraging the ability of the body’s immune system to effectively respond to oncogenic processes. The advent and rapid escalation of targeted cancer therapies has led to the emergence of sophisticated immuno-oncology agents. However, the historically high cost of these agents has compelled payers to initiate strategies to control utilization and manage costs. This activity will provide health care decision makers and managed care professionals with the required education on the principles of immuno-oncology and the mechanisms of action behind these novel treatments.


After completing the activity, participants should be better able to:
  • Characterize the role of the immune system in immunosurveillance and elimination of malignant cell lines with respect to cancer immunoediting
  • Describe the mechanisms of action of novel immuno-oncology agents such as PD-1 and PD-L1 inhibitors and CAR-T therapies
  • Describe key outcomes measures in immuno-oncology and characterize the importance of cumulative assessment of outcomes
  • Apply comprehensive analyses of clinical trial data pertaining to recently approved and investigational PD-1/PD-L1 inhibitors and CAR-T therapies
  • Characterize the incongruent application of traditional payer cost-sharing and benefit design approaches to the management of innovative immuno-oncology agents
  • Evaluate current and proposed payer initiatives for the funding and management of PD-1/PD-L1 inhibitors and CAR-T therapies
Opening Comments/Overview
Jeffrey Dunn, PharmD, MBA
Assessing the Clinical Benefits and Appropriate Use of Immuno-Oncology Agents
Joan H. Schiller, MD
Medical and Pharmacy Benefit Design Strategies for Immuno-Oncology Agents
Jeffrey Dunn, PharmD, MBA
Care Coordination Strategies to Enhance Patient Outcomes with Immuno-Oncology Agents
John Fox, MD, MHA
Audience Question and Answer Session

Key Takeaways and Closing Comments
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008162-9999-19-710-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email